William P. Allan - Concepedia

Author

William P. Allan

University of Pittsburgh

Also Known As

W P Allan, W. Allan, W.P. Allan, William Allan, William P Allan, William P. Allan

Publications

797

Citations

H-Index

Concepts

All Affiliations

University of Pittsburgh University of Manitoba UPMC Hillman Cancer Center

About

William P. Allan is an author at University of Pittsburgh specializing in medicine, cell biology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	421
2	Natural Sciences	1	1	66
3	Public Health	1	1	223
4	Allergy	1	1	66
5	Biochemistry	1	1	44

William P. Allan

Publications

774

Citations

H-Index

Page 1

	Year	Citations
Validating TrueAllele<sup>®</sup> DNA Mixture Interpretation*<sup>,†</sup> Mark W. Perlin, Matthew M. Legler, Cara E. Spencer, Journal of Forensic Sciences Genetic TestingGeneticsDna MixturesDna AnalysisMolecular Biology	2011	223
A genome wide search for alcoholism susceptibility genes Shirley Y. Hill, Sa Shen, Nicholas Zezza, American Journal of Medical Genetics Part B Neuropsychiatric Genetics	2004	107
The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Ebba U. Kurz, Steven E. Wilson, Kelly B. Leader, PubMed Chemoprevention StrategyEpigenetic ChangeConfers HypersensitivityCell DeathEtoposide Sensitization	2001	66
The Catalytic DNA Topoisomerase II Inhibitor Dexrazoxane (ICRF-187) Induces Differentiation and Apoptosis in Human Leukemia K562 Cells Brian B. Hasinoff, Michael E. Abram, Norman Barnabé, Molecular Pharmacology	2001	57
Differential induction of etoposide-mediated apoptosis in human leukemia HL-60 and K562 cells. M K Ritke, James M. Rusnak, J S Lazo, Molecular Pharmacology	1994	55
Mitindomide Is a Catalytic Inhibitor of DNA Topoisomerase II That Acts at the Bisdioxopiperazine Binding Site Brian B. Hasinoff, Andrew M. Creighton, Hanna Kozłowska, Molecular Pharmacology	1997	50
Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II Brian B. Hasinoff, Theodore I. Kuschak, Andrew M. Creighton, Biochemical Pharmacology BiochemistryCatalytic InhibitorTopoisomerase IiMedicineMechanism Of Action	1997	44
Collateral sensitivity to the bisdioxopiperazine dexrazoxane (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells Cheryl L. Fattman, William P. Allan, Brian B. Hasinoff, Biochemical Pharmacology Hematological MalignancyOncologyMedicineMixed-phenotype Acute LeukemiaBisdioxopiperazine Dexrazoxane	1996	40
Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells. M K Ritke, William P. Allan, Cheryl L. Fattman, Molecular Pharmacology	1994	38
Increased c-jun/AP-1 levels in etoposide-resistant human leukemia K562 cells Mary K. Ritke, Vladimir V. Bergoltz, William P. Allan, Biochemical Pharmacology Hematological MalignancyCancer ResearchC-jun/ap-1 LevelsApoptosisImmunology	1994	34

Page 1